Blog Archive
-
▼
2007
(18)
-
▼
September
(9)
- Ethicon Endo-Surgery, REALIZE™ Adjustable Gastric ...
- METABOLEX , PHASE 2 TRIAL OF MBX-802, Study Will A...
- DOV Pharmaceutical, Significant Body Weight and BM...
- Orexigen, positive results in two Phase I clinical...
- Metabolex and Astellas, to identify potential drug...
- Arena Pharmaceuticals, Continues Phase 3 BLOOM Obe...
- Salugen , GenoTrim - a DNA Customized Nutritional ...
- Genaera, Formation of Scientific Advisory Board fo...
- an obesity blog
-
▼
September
(9)
Saturday, September 29, 2007
Ethicon Endo-Surgery, REALIZE™ Adjustable Gastric Band For Morbid Obesity
September 28, 2007– Ethicon Endo-Surgery, Inc. announced the U.S. Food and Drug Administration (FDA) approved for marketing the REALIZE™ Adjustable Gastric Band, a surgical implant for weight reduction and improvement in obesity-related health conditions, such as type-2 diabetes, in individuals suffering from morbid obesity... Ethicon's Press Release -